Fig. 1 · Structure

Documents & Downloads

Aleglitazar

Cat. No. A12492 CAS 475479-34-6

PPAR-α/γ agonist

Aleglitazar is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PPARγ IC50 19 nM
PPARα IC50 38 nM

Cellular Effect

Cell Line Activity Value Description Reference
BHK-21 EC50 0.021 μM Agonist activity at human PPARgamma expressed in BHK21 cells assessed as SEAP activity by luciferase reporter transactivation assay [PMID: 19349176]

Aleglitazar Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Aleglitazar from 3 published references.

Aleglitazar In Vitro Studies

Aleglitazar significantly increased ABCA1 expression in primary human hepatocytes at all tested concentrations. In baby hamster kidney cells expressing human PPARα and a luciferase reporter, Aleglitazar yielded a half-maximal activation value of 5 nm. In primary mouse cortical neuronal cultures subjected to oxygen–glucose deprivation, Aleglitazar pretreatment protected against cell death compared with vehicle treatment, as quantified by LDH release. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Aleglitazar increases ABCA1 expression in primary human hepatocytes

Cell-based study · Primary human hepatocytes; five replicates of each treatment concentration [1]

Primary human hepatocytes were incubated with Aleglitazar at 0.013 µM, 0.064 µM or 0.32 µM for 6 hours. Aleglitazar significantly increased ABCA1 expression at all concentrations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ABCA1 expressionReported result Aleglitazar significantly increased ABCA1 expression at all concentrations[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.013 µM, 0.064 µM or 0.32 µM
Exposure duration
6 hours
Method
incubated
Vehicle
0.1% dimethyl sulfoxide
Methods and source locations

Compound reported in the paper: Aleglitazar

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Cell culture (S1, S2); Methods > Gene-expression microarray analysis (S12); Results > Lipid metabolic pathways (S63)

ABCA1 expression: ABCA1 expression; comparator: vehicle control — Results > Lipid metabolic pathways (S63)

Aleglitazar activates human PPARα in a reporter assay

Cell-based study · Baby hamster kidney cells (BHK21); human PPARα (amino acids 167–469); pFR-Luc luciferase reporter plasmid [2]

Baby hamster kidney cells expressing human PPARα and a luciferase reporter were incubated with Aleglitazar for 24 h. The half-maximal activation value was 5 nm.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PPARα; receptor transcriptional activityReported result half-maximal activation (EC50) values of 5 nm; maximum PPARα activation of sevenfold[2]

Literature-Reported Treatment Conditions

Exposure duration
24 h incubation in the presence of ligand
Method
medium containing the test or reference compound
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: dose. Removed after verification: value.
Methods and source locations

Compound reported in the paper: Aleglitazar

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Effects on PPAR transcriptional activity (S1, S5); Experimental Section (S45); Experimental Section > Transactivation assay (S48, S50, S51, S53, S54, S57, S59)

PPARα; receptor transcriptional activity: PPARα; receptor transcriptional activity; comparator: cells incubated at low, non-activating concentrations of the test compound — Results > Effects on PPAR transcriptional activity (S1, S5); Experimental Section > Transactivation assay (S59)

Aleglitazar protects cortical neurons during oxygen–glucose deprivation

Cell-based study · Primary neuronal cultures of mouse cerebral cortex; fetal C57BL/6N mice (E15); N = 5 independent cultures per condition. [3]

Primary mouse cerebral cortical neuronal cultures were pretreated with Aleglitazar at 125 μM for 24 h before 180 min oxygen–glucose deprivation. Within the deprivation condition, Aleglitazar protected against cell death compared with vehicle treatment, as quantified by LDH release.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
lactate dehydrogenase (LDH) release into the cell culture medium 24 h after OGDReported result Aleglitazar provided robust protection against cell death as quantified by LDH release after 180 min OGD[3]

Literature-Reported Treatment Conditions

Treatment concentration
125 μM
Exposure duration
24 h prior to OGD; 180 min OGD
Method
Neuronal cultures were pretreated with aleglitazar
Vehicle
0.25% DMSO in culture medium
Co-treatment
Other interventions in this design: oxygen–glucose deprivation (OGD). Compound effect isolated by the comparison: the effect of treatment with aleglitazar within the OGD condition.
Methods and source locations

Compound reported in the paper: Aleglitazar

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Cell culture experiments (S1, S9, S10); Methods > Induction of cerebral ischemia (S74, S76, S77); Results > Aleglitazar exerts beneficial effects on structural and functional outcomes of mild brain ischemia (S117, S118, S119)

lactate dehydrogenase (LDH) release into the cell culture medium 24 h after OGD: lactate dehydrogenase (LDH) release into the cell culture medium 24 h after OGD; comparator: Vehicle-treated neurons; MK-801 (10 μm) served as a positive control. — Methods > Induction of cerebral ischemia (S74); Results > Aleglitazar exerts beneficial effects on structural and functional outcomes of mild brain ischemia (S118)

Aleglitazar In Vivo Studies

Male mice undergoing MCAo/reperfusion received Aleglitazar at 3 mg/kg i.p. daily, starting on the day ischemia was induced. Compared with vehicle-treated control mice, Aleglitazar produced a statistically significant decrease of ~ 50% in infarct size assessed at 7 days. [3]

Aleglitazar reduces infarct size after cerebral ischemia in mice

Animal study · Male 129S6/SvEv mice; 30 min MCAo/reperfusion [3]

Male mice undergoing MCAo/reperfusion received Aleglitazar at 3 mg/kg i.p. daily, beginning on the day ischemia was induced. Compared with vehicle-treated control mice, treatment produced a statistically significant decrease of ~ 50% in infarct size assessed at 7 days.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Infarct size at 7 days after 30 min MCAo/reperfusion was assessed using NeuN-stained coronal brain sections.infarct size ~ 50%[3]

Conditions shared by the study groups

Route
i.p.
Treatment course
Treatment with aleglitazar was begun on the day on which brain ischemia was induced. Daily treatment with aleglitazar was continued until sacrifice
Vehicle
peanut oil, 0.9% saline, and ethanol (25:37.5:37:5, v/v)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Aleglitazar 3 mg/kgvehicle-treated control micethe higher dose (3 mg/kg) yielded a statistically significant and biologically meaningful decrease of ~ 50% in infarct size[3]
Aleglitazar 3 mg/kg
Model: Male 129S6/SvEv mice; 30 min MCAo/reperfusion
Methods and source locations

Compound reported in the paper: Aleglitazar

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animals (S52, S55); Methods > Induction of cerebral ischemia (S66, S67, S68, S70); Results > Aleglitazar exerts beneficial effects on structural and functional outcomes of mild brain ischemia (S114, S115)

Infarct size at 7 days after 30 min MCAo/reperfusion was assessed using NeuN-stained coronal brain sections.: Infarct size at 7 days after 30 min MCAo/reperfusion was assessed using NeuN-stained coronal brain sections.; comparator: vehicle-treated control mice — Methods > Induction of cerebral ischemia (S68); Results > Aleglitazar exerts beneficial effects on structural and functional outcomes of mild brain ischemia (S115)

Aleglitazar 3 mg/kg · Methods > Animals (S55); Methods > Induction of cerebral ischemia (S66, S67); Results > Aleglitazar exerts beneficial effects on structural and functional outcomes of mild brain ischemia (S115)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 475479-34-6
Applications PPAR-α/γ agonist
Formula C24H23NO5S
Molecular Weight 437.51
Synonyms R1439; RO0728804
SMILES
CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC(C(=O)O)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Aleglitazar Research References

  1. [1] Deehan R, Maerz-Weiss P, Catlett NL, et al. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes. PLoS One (2012). PMID: 22514701 DOI: 10.1371/journal.pone.0035012 Source material
  2. [2] Dietz M, Mohr P, Kuhn B, et al. Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem (2012). PMID: 22489042 DOI: 10.1002/cmdc.201100598 Source material
  3. [3] Boujon V, Uhlemann R, Wegner S, et al. Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice. J Mol Med (Berl) (2019). PMID: 31147725 DOI: 10.1007/s00109-019-01801-0 Source material

Added to your cart

View Cart Checkout
Loading...